18 slides from Inventurus Knowledge Solutions's earnings presentation, Jul 31, 2025
Slide 1: Exchange filing cover letter for investor presentation
July 31, 2025 BSE Limited National Stock Exchange of India Limited The Listing Department The Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, G Block, 25th Floor, Dalal Street Bandra Kurla Complex Fort, Mumbai 400 001 Bandra (East), Mumbai 400051 Maharashtra, India Maharas
Slide 2: IKS Health Q1 FY26 Investor Presentation
IKS Health Q1 FY 26 Investor Presentation 1
Slide 3: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 4: IKS Health - a comprehensive healthcare enablement platform empowering provider organizations
IKS Health - a comprehensive healthcare enablement platform empowering provider organizations US$260bn / US$34bn US$5tn 8% / 12% Total TAM / Outsourced Market TAM / Outsourced Market US Healthcare Addressable Expenditure (CY2024) (CY2023) CAGR (2023-2028E) Market1,2 The only Comprehensive platform t
Slide 5: IKS Health enables care transformation across the patient journey
IKS Health enables care transformation across the patient journey Automation Level Automation Level Automation Level Automation Level Optimized Patient Patient Prospective Pre-Visit Scheduling Financial Engagement Clinical Chart Clearance Hub Reviews Automation Level Automation Level Automation Leve
Slide 6: IKS Health: Strategic Pillars of execution
IKS Health: 5 Strategic Pillars of execution Establishing Leadership across AQuity Acquisition Differentiated Evolution Towards an AI-native. Agentic features; while Integration & Growth Market Outcome-Oriented Platform Manifest driving platform Optimization Strategy Company uniqueness - Launched Scr
Slide 7: Q1 - Strong growth while delivering continuous margin expansion
Q1 - Strong growth while delivering continuous margin expansion Deep Client Globally Diversified Growth At Scale Strong Margin Profile Relationships Workforce INR 7,401 mn 450+ 32% 12,368 Revenue from Enterprise level EBITDA Total Employees Operations customers 16% INR mn 3,213/43% 20% 2,260 / 502 YoY
Slide 8: Key Client Wins
Key Client Wins New partnership with Mission Community Hospital to drive financial outcomes and accountability with end-to-end revenue cycle across the hospital acute care and ambulatory surgery spaces New partnership with Bicycle Health leveraging IKS to manage revenue cycle, enabling rapid growth a
Slide 9: IKS Investment in WWMG MSO - Deal Overview
IKS Investment in WWMG MSO - Deal Overview WWMG Key Metrics Investment Structure $91M 90+ Investment Amount: $17M Annual Revenue Clinicians MSO Shareholding: 48% 30+ 20 Pre-money Valuation: $18.4M Years of Experience Specialities Revenue Share to MSO: 62.6% Transaction Structure WWMG will split into
Slide 10: Strategic Value & Expected Outcomes
Strategic Value & Expected Outcomes IKS 3.0 Evolution From Platform Provider to Transformation Partner Revenue Enhancement Cost Reduction Growth Opportunities ● 2% upside from reducing revenue ● 30-40% reduction in revenue cycle ● Value-based care: +124 patients per cycle leakages costs PCP ● 1.5-2%
Slide 11: Awards and Recognition
Awards and Recognition KS Health BW Best CFO & Finance Strategy Excellence Awards 2025I Excellence in Mergers and Acquisitions (Organizational Category) Best Woman CFO - Nithya Balasubramanian (Individual Category) 3rd Edition of the ET HR World Employee Experience Awards 2025 Exceptional Employee E
Slide 12: Q1 FY 26: Growing faster than market with improving margins
Q1 FY 26: Growing faster than market with improving margins Revenue EBITDA INR Mn INR Mn 2,262 2,378 7,240 7,401 15.6% YoY 36.3% YoY 6,401 1,745 32.1% 2.2% QoQ 31.2% 5.1% QoQ 27.3% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 PAT Adjusted PAT* INR Mn INR Mn 1,646 1,682 58.7% YoY 51.4% YoY 1,478 1
Slide 13: Q1 FY 26 - Improving EPS and maintaining high ROE
Q1 FY 26 - Improving EPS and maintaining high ROE EPS ₹ ROE % 57.7% YoY 2.0% QoQ EPS is calculated as profit for the period divided by weighted average Return on Equity is calculated as profit for the period divided by total number of equity shares as defined in IND AS 33. equity at the end of the peri
Slide 14: Q1 FY 26 - Continued strong cash generation supporting growth aspirations
Q1 FY 26 - Continued strong cash generation supporting growth aspirations OCF & FCF Net Debt INR Mn INR Mn 23.4% OCF 27.0% FCF Reported OCF and FCF are impacted by upfront guarantee payment of economic value add made to a new customer $5 million or INR 428 million 13
Slide 15: Financials - Summary INR millions
Financials - Summary INR millions INR Mn Particulars Q1 FY 26 Q4 FY 25 QoQ% Q1 FY 25 YoY% Revenue USD mn 87 84 3.0% 77 13.2% Revenue 7,401 7,240 2.2% 6,401 15.6% Other Income - Operating* - - 0.0% 34* 0.0% Forex Gain/ (Loss) 12 (24) -148.8% 4 178.7% Employee benefit expense excluding ESOP 3,871 3,74
Slide 16: Other KPI Metrics
Other KPI Metrics Particulars Q1 FY 26 Q4 FY 25 Q1 FY 25 Annualised Adjusted EBITDA per employee in INR mn 0.81 0.76 0.53 Revenue from Top 10 customers INR mn 3,213 2,842 2,211 Contribution from Top 10 customers 43.4% 39.3% 34.5% Revenue from Top 5 customers INR mn 2,349 1,944 1,403 Contribution fro
Slide 17: Dr. Garheng Kong – Board of Director Nominee
Dr. Garheng Kong, MD | PhD | MBA – Board of Director Nominee Experience ● Founder & Managing Partner, HealthQuest Capital ● 36 IPO/M&A exits ● Lead Independent Director, Labcorp ● Boards: Xeris Biopharma, Be The Match, Duke University Health System ● Former Partner at Intersouth & Sofinnova; roles at
Slide 18: Join the Movement
Join the Movement Grow, Scale, Thrive